Novo Nordisk Transfers Parkinson’s Cell Therapy to AI Startup Cellular Intelligence
Danish pharmaceutical giant Novo Nordisk has transferred global rights to its experimental Parkinson’s disease cell therapy, STEM-PD, to US-based AI startup Cellular Intelligence. This strategic deal allows Novo Nordisk to focus on core diabetes and obesity markets while retaining equity stakes and future royalties. Cellular Intelligence, backed by Mark Zuckerberg’s Chan Zuckerberg Initiative, will leverage its artificial intelligence platform to accelerate clinical development and optimize manufacturing for the Phase I/II trial. The agreement highlights a growing trend of integrating AI into biotechnology to enhance efficiency in complex regenerative medicine treatments.
Editorial summary awaiting refresh
Cross-source coverage
Wire timeline
Novo Nordisk Transfers Parkinson's Stem Cell Therapy to AI Startup Cellular Intelligence
Pharmaceutical giant Novo Nordisk has announced the transfer of its promising Parkinson's disease stem cell therapy, known as STEM-PD, to Cellular Intelligence, an artificial intelligence startup backed by Mark Zuckerberg. The acquisition marks a strategic shift in the development trajectory of the therapy, which is currently ready for Phase 2 clinical trials. Cellular Intelligence plans to leverage advanced AI technologies to significantly accelerate both the development timeline and the manufacturing processes associated with the cell therapy. This move highlights the growing intersection of biotechnology and artificial intelligence, where machine learning models are increasingly utilized to optimize complex biological production and drug discovery phases. By handing over the asset to a specialized AI-driven entity, Novo Nordisk aims to streamline the path to market for this potential treatment. The deal underscores the confidence investors and tech leaders have in applying computational power to solve longstanding challenges in regenerative medicine. This collaboration could set a precedent for how large pharmaceutical companies manage late-stage pre-clinical assets by partnering with agile, technology-focused startups to enhance efficiency and reduce costs in bringing novel therapies to patients suffering from neurodegenerative conditions.
QuartzCellular Intelligence Licenses Novo Nordisk’s Shelved Parkinson’s Cell Therapy
US biotech firm Cellular Intelligence has acquired global rights to Novo Nordisk’s discontinued cell therapy programme for Parkinson’s disease. This agreement comes seven months after the Danish pharmaceutical giant shut down its cell therapy unit in October 2025, laying off 250 employees. While financial terms remain undisclosed, Novo Nordisk will receive future milestones and royalties and make an equity investment in Cellular Intelligence. The therapy, an allogeneic pluripotent stem cell-derived dopaminergic progenitor treatment, is currently in a Phase I/II clinical trial and holds FDA fast-track designation. Cellular Intelligence, backed by tech tycoon Mark Zuckerberg, plans to leverage its AI-native platform to accelerate clinical development, reduce costs, and improve scalability. The company’s technology predicts cellular responses to external signals, using data from this programme to further train its foundation model. This transaction follows Novo’s strategic pivot away from cell therapies, which also saw Aspect Biosystems acquire other assets in January 2026. The deal ensures the continued clinical advancement of a promising treatment for Parkinson’s, a condition with no currently approved cell therapies.
Pharmaceutical TechnologyNovo Nordisk Transfers Parkinson’s Therapy to AI Biotech Cellular Intelligence
Novo Nordisk has transferred STEM-PD, an experimental stem-cell therapy for Parkinson’s disease, to Cellular Intelligence, an AI-driven biotechnology startup backed by Mark Zuckerberg. This move follows Novo’s decision to discontinue the therapy last October as part of a broader restructuring that prioritized its lucrative obesity and diabetes franchises, specifically Wegovy and Ozempic. Under the agreement, Novo Nordisk will acquire an equity stake in Cellular Intelligence and is eligible for future milestone payments and royalties, although specific financial terms were not disclosed. Cellular Intelligence plans to leverage its proprietary artificial intelligence platform to accelerate the development of STEM-PD, optimize manufacturing processes, and reduce production costs. The startup, which has raised over $60 million from investors including Khosla Ventures and the Chan Zuckerberg Initiative, aims to make the cell therapy commercially viable. This deal allows Novo to resolve loose ends from its cell-therapy unit shutdown while providing Cellular Intelligence with a clinical-stage asset to validate its AI-driven biological platform. The transaction highlights a growing trend of integrating AI into biopharmaceutical development to enhance efficiency and scalability in complex treatments like cell therapies.
The Next WebNovo Nordisk Transfers Parkinson’s Therapy to AI Startup Cellular Intelligence
Danish pharmaceutical giant Novo Nordisk has agreed to transfer an experimental Parkinson’s disease therapy to Cellular Intelligence, an artificial intelligence startup backed by Mark Zuckerberg. This unconventional deal reverses traditional pharmaceutical trends, with the large corporation handing over an early-stage asset to a smaller tech firm rather than acquiring it. Cellular Intelligence will assume responsibility for clinical development and manufacturing, utilizing its AI platform to optimize cell production and predict quality outcomes. In exchange, Novo Nordisk will receive milestone payments and royalties if the program succeeds, alongside a undisclosed equity stake in the Boston-based startup. The move follows Novo’s strategic decision to dismantle its cell-therapy division to focus on core areas like obesity and diabetes. Cellular Intelligence, which has raised over $60 million, has established a lab in Copenhagen and hired former Novo employees involved in the project. A mid-stage clinical trial is scheduled to begin early next year, aiming to transplant lab-grown dopamine-producing nerve cells into patients. This transaction highlights the growing integration of AI in biotech development and marks a shift in how major pharma companies manage non-core assets.
Financial PostNovo Nordisk Transfers Parkinson’s Therapy to AI Startup Cellular Intelligence
Novo Nordisk A/S has agreed to transfer an experimental cell therapy for Parkinson’s disease to Cellular Intelligence, an artificial intelligence startup backed by Mark Zuckerberg’s Chan Zuckerberg Initiative. This strategic move allows the Danish pharmaceutical giant to focus on its core obesity and diabetes sectors while potentially accelerating the development of the Parkinson's treatment through AI-driven optimization. Under the agreement, Boston-based Cellular Intelligence gains rights to the early-stage therapy and will manage its clinical trials, including a planned mid-stage study starting next year. Novo Nordisk will receive milestone payments and royalties if the program succeeds and has also purchased an undisclosed stake in the startup. The deal involves the transplantation of lab-grown, dopamine-producing nerve cells into patients' brains. Cellular Intelligence intends to use its AI platform to enhance cell production quality and predict survival rates, marking a reversal of traditional pharma deals where large companies typically acquire assets from smaller biotechs. The startup has established a lab in Copenhagen and hired former Novo employees who worked on the project. This transaction follows a similar recent agreement between Novo Nordisk and Aspect Biosystems.
Financial PostNovo Nordisk Transfers Parkinson’s Therapy to AI Startup Cellular Intelligence
Novo Nordisk A/S has agreed to transfer an experimental cell therapy for Parkinson’s disease to Cellular Intelligence, an artificial intelligence startup backed by Mark Zuckerberg’s Chan Zuckerberg Initiative. This strategic move allows the Danish pharmaceutical giant to focus on its core obesity and diabetes sectors while potentially accelerating the development of the Parkinson's treatment through AI-driven optimization. Under the agreement, Boston-based Cellular Intelligence gains rights to the early-stage therapy and will manage its clinical trials, including a planned mid-stage study starting next year. Novo Nordisk will receive milestone payments and royalties if the program succeeds and has also purchased an undisclosed stake in the startup. The deal involves the transplantation of lab-grown, dopamine-producing nerve cells into patients' brains. Cellular Intelligence intends to use its AI platform to enhance cell production quality and predict survival rates, marking a reversal of traditional pharmaceutical deals where large companies typically acquire assets from smaller biotechs. The startup has established a lab in Copenhagen and hired former Novo employees who worked on the project.
Financial PostCellular Intelligence Acquires Novo Nordisk’s Parkinson’s Cell Therapy Program
Cellular Intelligence has announced the acquisition of global rights to Novo Nordisk’s clinical-stage cell therapy program for Parkinson’s disease. This strategic deal involves an equity investment by Novo Nordisk in Cellular Intelligence, along with eligibility for future milestone payments and royalties, although specific financial terms remain undisclosed. The therapy, an allogeneic pluripotent stem-cell-derived dopaminergic progenitor treatment, is currently in a Phase ½ clinical trial and holds FDA Fast Track designation. Cellular Intelligence intends to leverage its AI foundation model, trained on millions of cellular perturbation conditions, to accelerate development, reduce manufacturing costs, and streamline commercialization timelines. To support this initiative, the company has appointed neurologist Nuno Mendonça as chief medical officer. This move follows reports that Novo Nordisk decided to discontinue certain internal cell therapy research efforts, including candidates for diabetes and heart disease, to focus on partnering with specialized entities capable of handling complex scientific and manufacturing challenges. The collaboration aims to deliver a meaningful, disease-modifying therapy for the approximately 12 million people worldwide affected by Parkinson’s.
JPost.com - The Jerusalem Post - All News from the Middle East, Israel, and the Jewish World